COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study - Takeaways - MDSpire

COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study

  • By

  • Quincy Hofsink

  • Birgit I Lissenberg-Witte

  • Sabine Haggenburg

  • Abraham Goorhuis

  • Mette D Hazenberg

  • Caroline E Rutten

  • Paul den Tex

  • Elisabeth G E de Vries

  • Astrid A M van der Veldt

  • Jeanet M Kemmeren

  • Nicolette F de Keizer

  • Peter C Huijgens

  • Avinash G Dinmohamed

  • Annika van Roon

  • Joyce Pijpers

  • Caren van Roekel

  • Susan van den Hof

  • Susan J M Hahné

  • Brechje de Gier

  • Jarom Heijmans

  • Inger S Nijhof

  • October 14, 2025

  • 0 min

Share

  • 1

    Patients with hematologic malignancies have the highest risk of severe COVID-19 compared to those with solid malignancies or no malignancies.

  • 2

    COVID-19 vaccination reduced the risk of severe outcomes in patients with hematologic malignancies by up to 74%, depending on various factors.

  • 3

    The risk of severe COVID-19 is particularly high in patients with recently diagnosed hematologic malignancies and those undergoing specific treatments.

  • 4

    Determinants of severe COVID-19 include the type of malignancy, time since diagnosis, and treatment regimens in patients with hematologic cancers.

  • 5

    This study provides critical insights to guide healthcare professionals in developing strategies for managing COVID-19 in hematologic cancer patients.

Original Source(s)

COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study

  • by Quincy Hofsink, Birgit I Lissenberg-Witte, Sabine Haggenburg, Abraham Goorhuis, Mette D Hazenberg, Caroline E Rutten, Paul den Tex, Elisabeth G E de Vries, Astrid A M van der Veldt, Jeanet M Kemmeren, Nicolette F de Keizer, Peter C Huijgens, Avinash G Dinmohamed, Annika van Roon, Joyce Pijpers, Caren van Roekel, Susan van den Hof, Susan J M Hahné, Brechje de Gier, Jarom Heijmans, Inger S Nijhof

  • October 14, 2025

Related Content

Long-term epidemiological patterns of pediatric infectious diseases in an urban district of Shanghai, 2015–2023

JinHuangJieDu (JHJD) formula attenuates SARS-CoV-2 infection by interrupting RBD-ACE2 binding and HIF-1α-dependent inflammation

Impact of COVID-19 history on the prevalence of coronary slow flow: a comparative study in unstable angina patients